kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus PDCD1 /PD1 Protein, Fc Tag (MALS verified), 100µg  

Recombinant Cynomolgus PDCD1 /PD1 Protein, Fc Tag (MALS verified), 100µg

Recombinant Cynomolgus PDCD1 /PD1 Protein, (Cyno PDCD1 / PD1 Fc Chimera) AA Leu 25 - Gln 167 was produced in human HEK293 cells, Fc Tag (MALS verified)

recombinant protein PDCD1, PD1, CD279, SLEB2

More details


Availability: within 7 days

390,00 €

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Recombinant Cynomolgus PDCD1 /PD1 Protein, Fc Tag (PD1-C5254) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # B0LAJ3).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 42.6 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) Polymorphisms Related to Iron Homeostasis Associate with Liver Disease in Chronic Hepatitis C"
Wróblewska, Woziwodzka, Rybicka et al
Viruses (2023) 15 (8)
(2) "Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy"
To, Cho
Pharmaceutics (2023) 15 (8)
(3) "Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy"
Kim, Cho, Min et al
Pharmaceuticals (Basel) (2023) 16 (8)
Showing 1-3 of 22271 papers.


(1) "Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies"
Authors: Yam Alice, et al.
Journal: US20180142022A1 2018
Application: ELISA